170 -3 (31/4) 2020 — Atakhodjaeva G.A., Mal G.S., — DYNAMICS OF EFFICIENCY OF COMBINED THERAPY OF CHRONIC HEART INSUFFICIENCY ON THE INDICATORS OF POSTINFARCT REMODELING OF THE LEFT VENTRICLE IN PATIENTS WITH METABOLIC SYNDROME

DYNAMICS OF EFFICIENCY OF COMBINED THERAPY OF CHRONIC HEART INSUFFICIENCY ON THE INDICATORS OF POSTINFARCT REMODELING OF THE LEFT VENTRICLE IN PATIENTS WITH METABOLIC SYNDROME

Atakhodjaeva G.A. -Tashkent Pediatric Medical Institute, Tashkent, Uzbekistan, Kursk state medical university, Russian Federation.

Mal G.S. -Tashkent Pediatric Medical Institute, Tashkent, Uzbekistan, Kursk state medical university, Russian Federation.

Baratova D.S. -Tashkent Pediatric Medical Institute, Tashkent, Uzbekistan, Kursk state medical university, Russian Federation.

Mirzalieva A.A. -Tashkent Pediatric Medical Institute, Tashkent, Uzbekistan, Kursk state medical university, Russian Federation.

Resume

The aim of this work is to study the anti-metabolic therapy in anti-remodeling efficiency of complex pharmacotherapy of CHF, including of perindopril, spironolakton and bisoprolol in patients with metabolic syndrome (MS). The study involved 197 male patients with chronic heart failure (CHF) II-III FC. Depending on the components of MS the patients were divided into 3 groups: Ist group (n=57), patients without MS; Group II (n=69), patients with a combination of dyslipidemia (DLP), hypertrigliceridemia (HTG) with abdominal obesity (AO) and arterial hypertension (AH); Group III (n=71) patients with a combination of AO, AH and DLP with diabetes 2 types. The progress of CHF against the background of MS is characterized by more severe symptoms and manifestations ofpost-infarction remodeling and function impairment of left ventricle, which was most expressed in a combination of diabetes 2 types with DLP, AH, AO and GTG.

Key worlds: chronic heart failure, metabolic syndrome, remodeling of the left ventricular function.

First page

695

Last page

699

For citation: Atakhodjaeva G.A., Mal G.S.2, Baratova D.S., Mirzalieva A.A., Dynamics of efficiency of combined therapy of chronic heart insufficiency on the indicators of postinfarct remodeling of the left ventricle in patients with metabolic syndrome//New Day in Medicine 3(31)2020 695-699 https://cutt.ly/axLpiwX

List of References

1. Атаходжаева Г.А. Качество жизни и функциональное состоя­ние почек у больных с хронической сердечной недостаточ­ностью и метаболическим синдромом // Журнал “Терапев­тический вестник Узбекистана”, Ташкент, 2G15 й, №2, 2G2- 2G7 стр. Atakhodjaeva G.A. Quality of life and functional state of kidneys in patients with chronic heart failure and metabolic syndrome // Therapeutic Journal of Uzbekistan, Tashkent, 2G15, №2, p. 2G2-2G7
2. Атаходжаева Г.А., Рахимов 0.М. Ролв метаболических факто­ров в развитии эндотелиальной дисфункции у больных с хро­нической сердечной недостаточностью// Журнал “Кардио­логия Узбекистана” 2015 г., №1 (35), стр 42-46. Atakhodjaeva G.A., Rakhimov Sh. M. The role of metabolic factors in the development of endothelial dysfunction in patients with chronic heart failure// Jourmal of Cardiology of Uzbekistan. 2015 ., №1 (35), p. 42-46
3. Курбанов Р.Д., Абдуллаев Т.А. Амиркулов Б.Д. и соавт. Акту­альные проблемы сердечной ресинхронизирующей терапии у больных с тяжелой формой ХСН //Кардиология Узбекистана. 2015. №3, С.79-85. Qurbanov R.D., Abdullaev T.A., Amirqulov B.D. and co-athours. Actual problems of cardiac resynchroniation therapy in patients with sevre chronic heart failure// Cardiology of Uzbekistan. 2015., №3-C, p. 79-85
4. Мареев Ю. В., Мареев В. Ю. Характеристика и лечение пациентов! с ХСН юсиитализированных в стационар. Кардиоло­гия. 2017;57 (S4):20-30. Mareev Y.V., Mareev V.Y. Characterization and treatment of patients with heart failure hospitalized in a hospital. Cardiology. 2017;57 (S4):20-30.
5. Поляков Д. С., Фомин И. В., Валикулова Ф. Ю. и др. Эпидеми­ологическая программа ЭПОХА – ХСН: декомпенсация хро­нической сердечной недостаточности в реальной клиничес­кой практике (ЭПОХА -Д – ХСН). Журнал Сердечная недостаточность. 2016;17 (5):299-305. Polyakov D.S., Fomin I.V., Vanikulova F.Y. and others. Epidemiological program EPOCH – CHF: decompensation of chronic heart failure in real clinical practice (EPOCH-D – CHF). Journal of Heart Failure. 2016;17 (5):299-305.
6. Резник Е.В. Особенности поражения органов-мишеней у больных с хронической сердечной недостаточносгъю. Диссерта­ция на соискание учеиой степене доктора медицинских наук. Москва. 2016; 500 с. Reznik Y.V. Features of target organ damage in patients with chronic heart failure. The dissertation for the degree of Doctor of Medical Sciences. Moscow.2016; p. 500.
7. Рекомендации ESC по диапюстике и лечению острой и хро­нической сердечной недостаточности 2016 (избранные поло­жения) //.Лцки Украчни – Medicine of Ukraine. – 2016. – №7­8 (203-204). – С. 8-12. ESC recommendations for the diagnosis and treatment of acute and chronic heart failure 2016 (selected provisionsy/Ёцки Украчни- Medicine of Ukraine. – 2016. – №7-8 (203-204). – С. 8-12.
8. Рабочая группа по диапюстике и лечению острой и хронической сердечной недостаточности Европейского Общества кардиологов (ESC) При участии: Ассоциации Сердечной недостаточности (АСЩ в составе ESC// Российский кар­диологический журнал. -2017. – №1 (141). – С7-81. Working Group on the Diagnosis and Treatment of Acute and Chronic Heart Failure of the European Society of Cardiology (ESC) With the participation of: Association of Heart Failure (ASH) as part of ESC // Russian Journal of Cardiology. -2017. – №1 (141). – С7­81.
9. Фомин И. В. Хроническая сердечная недостаточность в Рос­сийской Федерации: что сегодня мы знаем и что должны делать. Российский кардиологический журнал. 2016; (8):7-13. Fomin I.V. Chronic heart failure in the Russian Federation: what we know today and what we should do. Russian Journal of Cardiology.2016; (8):7-13.
10. AlFaleh H, Elasfar AA, Ullah A, AlHabib KF, Hersi A, Mimish L et al. Worsening heart failure in “real-world” clinical practice: predictors and prognostic impact: WHF in “real-world” clinical practice. European Journal of Heart Failure. 2017;19 (8):987-95.
11. Damman K., Gori M., Claggett B. et al. Renal Effects and Associated Outcomes During Angiotensin-Neprilysin Inhibition in Heart Failure. JACC Heart Fail. 2018.
12. Hoes MF, Grote Beverborg N, Kijlstra JD, Kuipers J, Swinkels DW, Giepmans BNG et al. Iron deficiency impairs contractility of human cardiomyocytes through decreased mitochondrial function: Impaired contractility in iron-deficient cardiomyocytes. European Journal of Heart Failure. 2018;20 (5):910-9.
13. Green JB, Bethel MA, Armstrong PW et al. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. New England Journal of Medicine. 2015;373 (3):232
14. Lipska KJ. Metformin Use in Patients With Historical Contraindications. Annals of Internal Medicine. 2017;166 (3):225.
15. Mant J, Doust J, Roalfe A, Barton P, Cowie M, Glasziou P et al. Systematic review and individual patient data meta-analysis of diagnosis of heart failure, with modelling of implications of different diagnostic strategies in primary care. Health Technology Assessment [Internet]. 2009 [cited on Febrary 1, 2018];13 (32).

170-695-699-3-31-2020-